Top diabetic drug goes off patent, prices to fall by 3rd https://ift.tt/b0KvrYt

The growing anti-diabetes market, valued at about Rs 17,000 crore, is set to witness action with generic versions of US firm Merck’s blockbuster Januvia being launched, reducing the cost of therapy by a third. This is on the heels of Sitagliptin, a relatively newer but vital anti-diabetic drug, losing patent protection in July.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Mxc0I1Z